Skip to main content
Clinical Trials/IRCT20220607055095N1
IRCT20220607055095N1
Completed
Phase 2

Evaluating the effects of the Atomoxetine and Trazodone combination on the number of apneas and apnea-hypopnea sleep index in obstructive sleep apnea patients referred to the sleep clinic of Imam Khomeini hospital.

Tehran University of Medical Sciences0 sites18 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
obstructive sleep apnea.
Sponsor
Tehran University of Medical Sciences
Enrollment
18
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Definite diagnosis of obstructive sleep apnea in medical history with AHI\>15 in polysomnography
  • lack of compliance treatment with CPAP or BIPAP
  • either the patient is unwilling to have surgery or they are not candidates for surgery in the opinion of the expert

Exclusion Criteria

  • commodities' existence (excluding controlled blood pressure, hyperlipidemia and diabetes)
  • any underlying cardiac disease, such as arrhythmia that is seen on the ECG
  • History of seizures, Panic disorder, Hyperventilation syndrome, Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder
  • Hypersensitivity to lidocaine, atomoxetine or trazodone, substances used in placebo
  • Taking any medication that leads to changes in the physiology of breathing, sleep / wake and muscles Taking any medication that leads to changes in the physiology of breathing, sleeping / waking and muscles
  • Inability to sleep in supine position

Outcomes

Primary Outcomes

Not specified

Similar Trials